Pharmaceutical Market Europe • October 2026 • 3

COMMENT

The power of social media

In our cover story this month, Danny Buckland looks at using the power of social media to break down obstacles preventing improved patient engagement.

As Danny says: “Social media is healthcare’s new superhero, full of high-flying promise and an armoury of positive patient and HCP connectivity, working to combat the obstacles standing in the way of improved patient outcomes.

“Its stage is expanding, with an ever-increasing number of search engines and platforms – from TikTok and Instagram to LinkedIn and Reddit – as the big tech players look to embed themselves as part of healthcare’s infrastructure.” Read more on page 26.

The article by Andrew Pitts looks at the next phase of oral GLP-1s and the three waves of innovation pharma leaders should watch. As Andrew says: “The approval of Eli Lilly’s orforglipron, sold as Foundayo, has changed the discussion around oral GLP-1s. Until recently, the GLP-1 receptor was widely seen as a poor target for conventional small-molecule chemistry.
 
Injectable peptides proved that the biology worked, but an oral small molecule that could deliver meaningful efficacy remained a much harder proposition. Foundayo’s approval on 1 April 2026 shows that this barrier can be overcome.” Find out more on page 16.

Dan Williams’ article highlights a rare opportunity to incentivise development of new treatments for rare diseases, as investment in rare disease biotechs has increased since the FDA’s Priority Review Voucher (PRV) scheme was renewed. As Dan says: “When a company is awarded a PRV, it is entitled to a cut in drug review times from ten months to six months; alternatively, it can sell the voucher.” Read more on page 19.

Our December issue will look at the value of patient engagement – creating improved outcomes for both patients and pharma. If you would like to make your voice heard on this topic, please get in touch at sales@pmlive.com

I hope you enjoy this issue!

Image

Iona Everson
Group Managing Editor

Image

Keep up to date with the latest developments in the UK and global healthcare marketplace – sign up to daily or weekly news alerts and fortnightly or monthly bulletins on specific topics at  www.pmlive.com/register

Image

THE TEAM
Editorial:
Group Managing Editor
Iona Everson

Executive Director
Karl Equi

Sales:
Business Director
Tara Lovegrove

EDITORIAL ADVISORY BOARD
Philip Atkinson
Founder of Hive-Logic, Lifescience Transformation

Uday Bose
General Manager, UK, GSK

Dr Luc Hermans
VP commercial planning and operations Europe, Asia, Middle East, Gilead Sciences

Stefan Janssens
President EMEA, Cegedim Dendrite

John Morris
Partner, KPMG

Paul Pay
Chief business development officer, Norgine

Mark Rothera
Chief executive officer, Orchard Therapeutics

Ian Talmage
Senior vice president, global marketing, general medicine, Bayer Pharmaceuticals

PUBLISHED BY
PMGroup Worldwide Ltd
44 Maiden Lane
Covent Garden
London
WC2E 7LN
Tel: +44 (0)1372 414200
Fax: +44 (0)1372 414201


CONTACT US
General enquiries: info@pmlive.com
Editorial: editor@pmlive.com
Advertising: sales@pmlive.com
Subscriptions: subscriptions@pmlive.com

Views expressed by the contributors do not necessarily represent those of the publisher, editor or staff.

© 2026 PMGroup
All rights reserved. No part of this publication may be copied, reproduced, transmitted, photocopied, recorded or stored on any retrieval system without the prior written consent of the publishers.

The magazine is also available at the following subscription rates: £120 UK, £180 Europe, £210 RoW

Image